A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Clinical trial NCT06568939 · RECRUITING

Trial details

NCT number: NCT06568939
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2025-01-20
Primary completion: 2028-02-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.